Viropharma acquires Swedish orphan drug firm DuoCort
This article was originally published in Scrip
Executive Summary
ViroPharma, an Exton, Pennsylvania-based firm whose products include treatments for the rare genetic disorder hereditary angioedema (HAE) and for GI infections caused by Staphylococcus aureus and Clostridium difficile, has agreed to pay up to around $165 million to acquire DuoCort Pharma, the Swedish firm awaiting European approval for a drug to treat the rare condition Addison's disease and other conditions causing adrenal insufficiency in adults.